+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Treatment of acutely exacerbated including highly agitated schizophrenic patients with oral risperidone



Treatment of acutely exacerbated including highly agitated schizophrenic patients with oral risperidone



European Neuropsychopharmacology 13(Supplement 4): S297




(PDF emailed within 1 workday: $29.90)

Accession: 035980825

Download citation: RISBibTeXText


Related references

Initial use of risperidone in the treatment of acutely exacerbated schizophrenic patients--an interim analysis. Fortschritte der Neurologie-Psychiatrie 71(5): 249-254, 2003

Olanzapine orally disintegrating tablet vs. risperidone oral solution in the treatment of acutely agitated psychotic patients. General Hospital Psychiatry 30(4): 367-371, 2008

Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. Journal of Psychopharmacology 24(7): 987-994, 2010

A naturalistic multicenter study of intramuscular olanzapine in the treatment of acutely agitated manic or schizophrenic patients. European Psychiatry 21(8): 539-543, 2006

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting. Human Psychopharmacology 23(1): 61-67, 2007

Pharmacological management of acutely agitated schizophrenic patients. Current Pharmaceutical Design 11(19): 2471-2477, 2005

Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica 87(2): 86-91, 1993

A post hoc analysis of transitioning to oral treatment with olanzapine or haloperidol after 24-hour intramuscular treatment in acutely agitated adult patients with schizophrenia. Clinical Therapeutics 27(10): 1612-1618, 2005

Patterns of prescription and effectiveness in a European cohort of acutely agitated schizophrenic or bipolar patients. 2007

Risperidone: an open-label, observational study of the efficacy, tolerability, and prescribing behavior in acutely exacerbated patients with schizophrenia. Journal of Clinical Psychopharmacology 25(4): 293-300, 2005

A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients. European Neuropsychopharmacology 10(Supplement 3): S304, 2000

Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 34(3): 537-540, 2010

Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. Journal of Clinical Psychiatry 61(3): 209-214, 2000

Fine-tuning risperidone dosage for acutely exacerbated schizophrenia: clinical determinants. Psychopharmacology 172(4): 393-399, 2003

An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. Journal of Clinical Psychopharmacology 33(6): 747-752, 2014